Corporate
May 20, 2011
Biotech Deals Use Milestone Payments
Lawyers are negotiating more mergers and acquisitions among biotechnology and medical device companies, but the deals are complicated by structures that include an upfront fee plus later payments when milestones are reached.
Daily Journal Staff Writer
There's an upside and a downside for lawyers who negotiate mergers and acquisitions among biotechnology and medical device companies: They're seeing more transactions, but the deals are increasingly complicated.
Major pharmaceutical companies and device manufacturers want to buy smaller firms or their technology, but they don't want to do it in one big outlay of cash. Instead, they'r...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In